No Picture
News

EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its… Click here to view original post… […]

No Picture
News

EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that management will host a conference call to highlight interim data from its ongoing Phase… Click here to view original post… […]

No Picture
News

EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

WATERTOWN, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that a late-breaking abstract highlighting topline data for the Phase 1 DAVIO trial of EYP-1901… Click here to view original post… […]

No Picture
News

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company expects to receive a nine month extension on DEXYCU®’s pass-through payment… Click here to view original post… […]

No Picture
News

EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index

WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company will be added to the small-cap Russell 2000® Index and the… Click here to view original post… […]